


ABSTRACT

This invention provides a compound of the formula (I):



5

(I)

or the pharmaceutically acceptable salts thereof, wherein Y¹, Y², Y³ and Y⁴ are independently selected from N, CH, etc.; R¹ is H, C₁₋₈ alkyl, etc.; Q¹ is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C₁₋₆ alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R² is H, C₁₋₄ alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C₁₋₄ alkyl, etc.; m is 0, 1 or 2; R³ and R⁴ are independently selected from H and C₁₋₄ alkyl; R⁵ is H, C₁₋₄ alkyl, etc.; Q² is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.